TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01439750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
Study: NCT01909830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A : Gemcitabine + Pemetrexed
Description: Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days.
Study: NCT02968849

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose \> 10\^6 cell culture infectious dose 50% (CCIDv50) and \< 1 × 10\^8 CCIDv50 (nominal dose of 10\^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120/MF59
Description: Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for injection, 0.9% delivered IM
Study: NCT02365558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally
Study: NCT00393991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
Study: NCT02946177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: 0.5 mL of sterile Saline administered im
Study: NCT01162473

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Oral Immunotherapy
Description: Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Oral Immunotherapy
Description: Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milk Protein Powder
Description: Milk protein powder will be administered in incremental doses during the desensitization protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milk Protein Powder
Description: Milk protein powder will be administered in incremental doses during the desensitization protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Challenge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Challenge
Study: NCT05620056

Intervention type: DRUG
Intervention: chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
Description: medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
Study: NCT00124072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg daily
Description: Simvastatin 20 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg daily
Description: Simvastatin 20 mg tablet once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 2 mg + vitamin B12 1 mg daily
Description: Folic acid 2 mg + vitamin B12 1 mg tablet once daily
Study: NCT00561587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel®
Description: dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
Study: NCT01187134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Change Management
Description: Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
Study: NCT03513289

Intervention type: OTHER
Intervention: Patient, Carer, and Clinician Interviews
Description: Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
Study: NCT02134067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
Study: NCT00124072

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 2 mg + vitamin B12 1 mg daily
Description: Folic acid 2 mg + vitamin B12 1 mg tablet once daily
Study: NCT02727517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early (≤ 60 seconds) cord clamping
Description: If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed (≥ 180 seconds) cord clamping
Description: If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
Study: NCT02929862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-55716
Description: For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
Study: NCT00124072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80 mg daily
Description: Simvastatin 80 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80 mg daily
Description: Simvastatin 80 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo vitamin B12/folic acid tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo vitamin B12/folic acid tablet once daily
Study: NCT00995436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extraoral anchorage
Description: Extra oral anchorage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miniscrews
Description: Intraoral skeletal anchorage using mini screws

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nance
Description: Intraoral dental anchorage by using Nance palatal arch on molars
Study: NCT03402191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: l-arginine for thalassemia with pulmonary hypertension
Study: NCT01558232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibion Bionic Leg
Description: The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
Study: NCT02702947

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prunus domestica extract
Description: Prosman 1 capsule twice a day
Study: NCT03611049

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose Vitamin D3
Description: High dose arm- 5000IU given daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Vitamin D3
Description: Low dose arm-800 IU given daily
Study: NCT03267407

Intervention type: OTHER
Intervention: Preemptive high-dose Fluconazole
Description: Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.

Intervention type: OTHER
Intervention: Preemptive high-dose Fluconazole
Description: Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.

Intervention type: OTHER
Intervention: Preemptive high-dose Fluconazole
Description: Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
Study: NCT03402191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil for thalassemia with pulmonary hypertension
Study: NCT01001767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: Lovaza one gram twice a day for 24 weeks
Study: NCT01444508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer-lactate SAD
Description: Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HES 130/04
Description: Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD.
Study: NCT04204798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~2. Propofol sedation is administered when considered necessary.
Study: NCT01001767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00589706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAb-425
Description: MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
Study: NCT01107392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
Study: NCT02368600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Description: On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
Study: NCT00369850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Study: NCT03750240

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sodium (Na) Magnetic Resonance Imaging (MRI)
Description: Two Na data will be acquired:~1. FLORET without Inversion Recovery (IR), and~2. FLORET with IR

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast- Enhanced (DCE) MRI
Description: DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
Study: NCT03771807

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beauty From Within
Description: one scoop of product mixed in 8-16 ounces of water consumed once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one scoop of product mixed in 8-16 ounces of water consumed once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial cleansing
Description: All subjects will use a cosmetic instrument to clean on one half of their face daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Facial cleansing
Description: All subjects will use a cosmetic instrument to clean on one half of their face daily
Study: NCT03865238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71vac
Description: Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
Study: NCT03815812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306
Description: Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
Study: NCT01985165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imrecoxib
Study: NCT01107704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Support Intervention
Description: Multifaceted family support intervention
Study: NCT00369850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DEXA)
Description: Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DEXA)
Description: Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Study: NCT03067480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPro2 Professional CGM
Description: Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPro2 Professional CGM
Description: Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
Study: NCT00700063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical Gel
Description: 0.005%, two days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical Gel
Description: 0.01%, two days treatment
Study: NCT00369850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DEXA)
Description: Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Study: NCT00700063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Topical Gel
Description: 0.015%, two days treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: two days treatment
Study: NCT00369850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DEXA)
Description: Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine X-ray
Description: Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine X-ray
Description: Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
Study: NCT03960606

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PUR1900
Description: PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PUR1900
Description: PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
Study: NCT00369850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine X-ray
Description: Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine X-ray
Description: Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
Study: NCT02165943

Intervention type: DEVICE
Intervention: Vitoss
Description: Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.

Intervention type: DEVICE
Intervention: Vitoss
Description: Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
Study: NCT03519997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembroluzumab 200mg IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab 3mg/kg IV weekly
Study: NCT01814865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg PO OD x 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO OD x 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: 1 mg PO OD x 2 weeks
Study: NCT00508105

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subscapularis peel
Description: Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osteotomy
Description: This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
Study: NCT02598869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: injection of triamcinolone acetonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: injection of triamcinolone acetonide
Study: NCT03163134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Drain
Study: NCT01916824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any FDA Approved Antidepressant
Description: Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.